U.S. markets closed

Tottenham Acquisition I Limited (TOTA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
10.88+0.05 (+0.46%)
At close: 11:56AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close10.83
Open10.83
Bid10.80 x 3000
Ask10.87 x 1800
Day's Range10.75 - 10.88
52 Week Range10.30 - 11.25
Volume12,755
Avg. Volume14,212
Market Cap40.369M
Beta (5Y Monthly)0.05
PE Ratio (TTM)N/A
EPS (TTM)-0.24
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • WeissLaw LLP Reminds CPAA, TOTA, and LFAC Shareholders About Its Ongoing Investigations
      PR Newswire

      WeissLaw LLP Reminds CPAA, TOTA, and LFAC Shareholders About Its Ongoing Investigations

      If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

    • Tottenham Acquisition I Limited Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Clene Nanomedicine, Inc.
      PR Newswire

      Tottenham Acquisition I Limited Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Clene Nanomedicine, Inc.

      Tottenham Acquisition I Limited (Nasdaq: TOTA, TOTAU, TOTAW, TOTAR) ("Tottenham"), a publicly traded special purpose acquisition company, announced today that its subsidiary, Chelsea Worldwide Inc., has filed with the U.S. Securities and Exchange Commission ("SEC") a registration statement on Form S-4 (the "Registration Statement"), which includes a preliminary proxy statement/consent solicitation statement/prospectus, in connection with its recently-announced proposed business combination with Clene Nanomedicine, Inc. ("Clene"), a clinical-stage biopharmaceutical company developing a potential therapeutic nanocatalyst for the treatment of neurodegenerative diseases in addition to a nanotechnology based-therapy with antiviral applications.

    • SHAREHOLDER ALERT: WeissLaw LLP Investigates Tottenham Acquisition I Limited
      PR Newswire

      SHAREHOLDER ALERT: WeissLaw LLP Investigates Tottenham Acquisition I Limited

      WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Tottenham Acquisition I Limited ("Tottenham" or the "Company") (NASDAQ: TOTA, TOTAU, TOTAW, TOTAR) in connection with the Company's proposed merger with privately-held clinical-stage biopharmaceutical company, Clene Nanomedicine, Inc. ("Clene"). Under the terms of the merger agreement, Tottenham will acquire Clene through a reverse merger that will result in Clene becoming a public company listed on the Nasdaq Capital Market. Additionally, Clene shareholders will be entitled to receive earn-out consideration of up to an additional 8.33 million shares of the newly combined company's common stock, subject to the new company achieving certain share price thresholds prior to certain future dates or meeting certain Covid-19 clinical trial targets. The proposed transaction values Clene at $542.5 million.